All In Biotech

Free tool

FAERS Monitor: Kitabis Pak

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205433 or its brand name (Kitabis Pak, Tobramycin). Reports on generic versions are filed under their own applications.

Reports

13,080

Serious

10,454

80% of reports

Hospitalization

6,400

Death reported

1,288

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use988
  • pneumonia838
  • infective pulmonary exacerbation of cystic fibrosis710
  • dyspnoea708
  • drug ineffective696
  • acute kidney injury690
  • hospitalisation562
  • death509
  • infection508
  • cystic fibrosis495
  • cough494
  • condition aggravated461
  • pyrexia428
  • fatigue410
  • nausea379

Reports by year received

View as table
YearReports
200480
200597
200676
2007124
200890
200999
2010101
2011207
2012188
2013164
2014272
2015444
2016513
2017592
20181,110
20191,724
20201,506
20211,081
20221,028
2023866
20241,063
2025933
2026722

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,079 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal710241.1223.2147,444
cystic fibrosisSignal495157.8144.170,099
acute kidney injurySignal6907.36.83,741
hospitalisationSignal5625.95.42,290
infectionSignal5085.75.21,951
pneumoniaSignal8384.23.92,043
coughSignal4942.82.6592
condition aggravatedSignal4612.42.2396
dyspnoeaSignal7082.01.9369
pyrexia4282.01.8213
off label use9881.81.7376
death5091.00.91
drug ineffective6960.80.820
fatigue4100.80.812
nausea3790.80.727

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.